BioNTech’s stock sank toward a more than two-year low Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply below expectations, weighed down by inventory writedowns by COVID-19 vaccine collaboration partner Pfizer.
Source link
